This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
Wes Yin, PhD
Advertisement
Articles by Wes Yin, PhD
This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.
Advertisement
Latest Updated Articles
- The Value of Survival Gains in Myelodysplastic Syndromes
January 16th 2017
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5